{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Stryker Corp. Experiences Valuation Adjustment Amidst Competitive Market Landscape
Stryker Corp. has recently adjusted its valuation, with a current P/E ratio of 34 and a Price to Book Value of 7.01. Key financial metrics include an EV to EBIT of 31.29 and a PEG ratio of 1.86, reflecting strong operational efficiency and competitive positioning within the industry.
Is Stryker Corp. overvalued or undervalued?
As of October 17, 2025, Stryker Corp. is considered overvalued with a P/E ratio of 34, an EV to EBITDA ratio of 25.94, and a PEG ratio of 1.86, indicating it trades at a premium compared to peers like Abbott Laboratories and Medtronic, while also underperforming the S&P 500.
Stryker Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape
Stryker Corp. has recently adjusted its valuation, with a current P/E ratio of 34 and a price-to-book value of 7.01. The company’s performance metrics show mixed results compared to the S&P 500, and its valuation is competitive within the Pharmaceuticals and Biotechnology sector.
Is Stryker Corp. overvalued or undervalued?
As of October 17, 2025, Stryker Corp. is considered overvalued with a valuation grade of expensive, reflected by its high P/E ratio of 34 compared to peers like Abbott Laboratories and Medtronic, and a stock performance of 4.08% over the past year, underperforming the S&P 500's 14.08%.
Is Stryker Corp. overvalued or undervalued?
As of October 17, 2025, Stryker Corp. is considered overvalued with a P/E ratio of 34 and a valuation grade of expensive, despite recent stock performance outpacing the S&P 500 in the short term, as its year-to-date and one-year returns lag behind the broader market.
Stryker Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead
Stryker Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. Current moving averages and MACD indicators reflect a bearish trend, while On-Balance Volume metrics suggest declining momentum. Despite a 3.0% increase over the past year, the stock has faced short-term challenges.
Stryker Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
Stryker Corp. has recently revised its evaluation amid changing market conditions. The stock is priced at $369.02, reflecting a slight increase from the previous close. Over the past year, Stryker's return has been 2.12%, trailing behind the S&P 500's performance, with current indicators suggesting a mildly bearish sentiment.
Is Stryker Corp. technically bullish or bearish?
As of September 12, 2025, Stryker Corp. is in a mildly bearish trend, indicated by bearish MACD readings and underperformance against the S&P 500, despite some daily moving averages showing mild bullishness.
Is Stryker Corp. overvalued or undervalued?
As of August 15, 2025, Stryker Corp. is considered very expensive and overvalued with a P/E ratio of 34, significantly higher than peers like Abbott Laboratories and Medtronic, and despite a year-to-date return of 4.94%, it underperforms the S&P 500's 12.22% return.
Stryker Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Stryker Corp. has recently revised its evaluation amid changing market conditions, with its stock priced at $377.11. The company has seen a 1.85% return over the past year, underperforming the S&P 500. Technical indicators present mixed signals, reflecting a cautious sentiment surrounding the stock's performance.
Is Stryker Corp. technically bullish or bearish?
As of June 18, 2025, the trend has shifted to mildly bullish, supported by a bullish MACD on the weekly chart and positive signals from Bollinger Bands and moving averages, despite some bearish indicators on the monthly timeframe.
Is Stryker Corp. overvalued or undervalued?
As of April 30, 2025, Stryker Corp. is considered very expensive with a P/E ratio of 34, significantly higher than industry peers like Abbott Laboratories and Thermo Fisher Scientific, indicating it may be overvalued despite recent positive returns.
Who are in the management team of Stryker Corp.?
As of March 2022, Stryker Corp.'s management team includes Chairman and CEO Kevin Lobo, Lead Independent Director Allan Golston, and Independent Directors Mary Brainerd, Srikant Datar, and Roch Doliveux, along with Director Giovanni Caforio. They are responsible for the company's strategic direction and governance.
What does Stryker Corp. do?
Stryker Corporation is a medical technology company specializing in various medical technologies, with a market cap of approximately $142.69 billion and a net profit of $654 million as of March 2025. Key metrics include a P/E ratio of 34.00 and a dividend yield of 0.87%.
How big is Stryker Corp.?
As of Jun 18, Stryker Corp. has a market capitalization of $142.69 billion, with net sales of $23.22 billion and a net profit of $2.86 billion over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
